Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects.

Aim: Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects of food and ethnicity on the pharmacokinetics (PKs) and safety of venadaparib after a single oral administration in healthy Korean, Cauc...

Descripción completa

Detalles Bibliográficos
Publicado en:Investigational New Drugs Vol. 42; no. 1; pp. 80 - 89
Autores principales: Kim, Hyun Chul, Yang, Eunsol, Lee, Soyoung, Oh, Jaeseong, Lee, Myongjae, Lee, ChaeEun, Ha, Kyoung Soo, Lee, Won Sik, Jang, In-Jin, Yu, Kyung-Sang
Formato: research tables/charts randomized controlled trial Journal Article
Publicado: Springer Nature Feb2024
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=175636726&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 175636726
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01676997
        OH2
      jtl: Investigational New Drugs
      issn: 01676997
      maglogo: N
    pubinfo:
      dt: Feb2024
      vid: 42
      iid: 1
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        175636726
        174230156
        175636726
        175636726
        10.1007/s10637-023-01405-z
        175636726
      ppf: 80
      ppct: 9
      formats:
      tig:
        atl: Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects.
      aug:
        au:
          Kim, Hyun Chul
          Yang, Eunsol
          Lee, Soyoung
          Oh, Jaeseong
          Lee, Myongjae
          Lee, ChaeEun
          Ha, Kyoung Soo
          Lee, Won Sik
          Jang, In-Jin
          Yu, Kyung-Sang
        affil: https://ror.org/04h9pn542 Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, 101, Daehak-ro, Jongno-gu, 03080, Seoul, Republic of Korea
      sug:
        subj:
          Enzyme Inhibitors Pharmacokinetics
          Patient Safety
          Administration, Oral
          Enzyme Inhibitors Administration and Dosage
          Koreans
          White Persons
          Chinese Persons
          Food
          Drug-Food Interactions
          Drug Tolerance
          Human
          Crossover Design
          Randomized Controlled Trials
          Random Assignment
          Male
          Fasting
          Blood Specimen Collection
          Confidence Intervals
          Comparative Studies
          Descriptive Statistics
          Meals
          Adult
          Middle Age
          South Korea
          Funding Source
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Male
      ab: Aim: Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects of food and ethnicity on the pharmacokinetics (PKs) and safety of venadaparib after a single oral administration in healthy Korean, Caucasian, and Chinese male subjects. Methods: In this randomized, open-label, single-dose, two-sequence, two-period, and crossover study, Korean and Caucasian subjects received venadaparib 80 mg in each period (fasted or fed state) with a seven-day washout. In an open-label, single-dose study, Chinese subjects received venadaparib 80 mg only in the fasted state. Serial blood samples were collected up to 72 h post-dosing. Results: Twelve subjects from each ethnic group completed the study. The geometric mean ratios (90% confidence intervals) of the maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from time zero to the last measurable time point (AUClast) of venadaparib for the fed to fasted state were 0.82 (0.7457–0.9094) and 1.02 (0.9088–1.1339) in Koreans, and 0.77 (0.6871–0.8609) and 0.96 (0.9017–1.0186) in Caucasians, respectively. No statistically significant differences were observed in Cmax (P-value = 0.45) or AUClast (P-value = 0.30) among the three ethnic groups. A single venadaparib dose was well-tolerated. Conclusion: The overall systemic exposure of venadaparib was not affected by the high-fat meal, despite delayed absorption with a decreased Cmax in the fed state. The PK profiles were comparable among the Korean, Caucasian, and Chinese subjects. A single venadaparib 80 mg dose was safe and well-tolerated in both fasted and fed states.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N